Sanofi Commits Up to $8 Billion to Expand Regeneron Alliance on Next-Gen Antibodies

Regeneron (REGN) reported positive clinical data for ubamatamab in ovarian cancer and trevogrumab in obesity. Ubamatamab showed a 73% response rate in LGSOC patients, while trevogrumab preserved lean mass in obesity patients. Both drugs are in clinical trials, with REGN planning further studies. REGN stock is currently down 2.08%.

Regeneron Pharmaceuticals (REGN) reported positive initial data from a Phase 1/2 trial of ubamatamab for low-grade serous ovarian cancer, with a 73% response rate. The company plans further trials and FDA discussions. REGN is modestly undervalued with a GF Value of $907.43, a GF Score of 88, and a P/E ratio of 18.2x, matching its 5-year median.

Regeneron (REGN) shares fell 4% after expanding its alliance with Sanofi, with Sanofi paying $1B upfront and up to $7B in milestones for new antibodies. The deal leaves Dupixent profit-sharing terms unchanged, disappointing investors who expected better terms. Shares later recovered slightly to close down 2.9% at $736.56.

Sanofi and Regeneron have entered an $8 billion drug deal, with Sanofi paying $1 billion upfront and the rest tied to clinical milestones. The deal focuses on developing an experimental drug, REGN20423, for atopic dermatitis, which is currently in early-stage testing. The first milestone payment of $1 billion is contingent on the drug advancing to late-stage trials.

Regeneron Pharmaceuticals (REGN) reported early-stage trial results for ubamatamab, showing 73% efficacy in ovarian cancer patients but 90% adverse events. REGN plans a Phase 3 trial. GF Value™ suggests REGN is 19.9% undervalued at $726.86. GF Score™ is 88/100. Insiders sold $12.9M shares in 12 months.

Regeneron Pharmaceuticals (REGN) reported Phase 1/2 trial data for ubamatamab, an ovarian cancer therapy. While all 19 patients experienced adverse events, 73% of heavily pretreated patients showed partial responses. Regeneron plans a Phase 3 trial and FDA data submission.